ERBB2 and breast carcinoma: Strategy of targeting HER2 in combination with chemotherapy had been the standard-of-care for patients detected with HER2-positive (IHC3 + or IHC2 + and ISH +) breast cancer (BC) and gastric cancer (GC) over decades by demonstrating survival benefit in the patient subset [2–4].